Protective effect of an Anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation

Martín, Xavier; Silva, M Da; Virieux, Silvina Ramella; Aïssa, A. Hadj; Buffet, Renaud; Tiollier, Jérôme; Dubernard, Jean Michel

doi:10.1016/s0041-1345(00)00849-6

Cited by 17 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized trials of recipient preconditioning with perioperative high‐dose erythropoietin, with the aim of harnessing a nephroprotective effect observed in animal models, have not demonstrated any effect in reducing the incidence of DGF after deceased‐donor kidney transplantation . Investigations into perfusing the graft or treating the recipient with a monoclonal antibody against lymphocyte function‐associated antigen 1 (LFA 1) have not progressed to clinical application.…”

Section: Recipient Intervention To Avoid Dgfmentioning

confidence: 99%

Prediction, prevention, and management of delayed graft function: where are we now?

Nashan

Abbud-Filho

Citterio

2016

Clinical Transplantation

View full text Add to dashboard Cite

Delayed graft function (DGF) remains a major barrier to improved outcomes after kidney transplantation. High-risk transplant recipients can be identified, but no definitive prediction model exists. Novel biomarkers to predict DGF in the first hours post-transplant, such as neutrophil gelatinase-associated lipocalin (NGAL), are under investigation. Donor management to minimize the profound physiological consequences of brain death is highly complex. A hormonal resuscitation package to manage the catecholamine "storm" that follows brain death is recommended. Donor pretreatment with dopamine prior to procurement lowers the rate of DGF. Hypothermic machine perfusion may offer a significant reduction in the rate of DGF vs simple cold storage, but costs need to be evaluated. Surgically, reducing warm ischemia time may be advantageous. Research into recipient preconditioning options has so far not generated clinically helpful interventions. Diagnostic criteria for DGF vary, but requirement for dialysis and/or persistent high serum creatinine is likely to remain key to diagnosis until current work on early biomarkers has progressed further. Management centers on close monitoring of graft (non)function and physiological parameters. With so many unanswered questions, substantial reductions in the toll of DGF in the near future seem unlikely but concentrated research on many levels offers long-term promise.

show abstract

Section: Recipient Intervention To Avoid Dgfmentioning

confidence: 99%

Prediction, prevention, and management of delayed graft function: where are we now?

Nashan

Abbud-Filho

Citterio

2016

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…Animal experiments using anti-LFA-1 monoclonal antibodies (mAbs) indicate that the LFA-1/ICAM interaction is involved in the pathogenesis of allergic contact dermatitis (Scheynius et al 1996), arthritis (Issekutz 1998), transplant rejection (Poston et al 2000), and ischemia/reperfusion injury (Martin et al 2000). Indeed, treatment with a blocking anti-LFA-1 mAb led to significant clinical effects in psoriasis patients (Gottlieb et al 2002).…”

Section: Lfa-1 Inhibition By Statinsmentioning

confidence: 99%

Lymphocyte Function-Associated Antigen-1 Blockade by Statins: Molecular Basis and Biological Relevance

Weitz‐Schmidt

2003

Endothelium

View full text Add to dashboard Cite

Lymphocyte function-associated antigen-1 (LFA-1) belongs to the integrin family and plays an important role in leukocyte trafficking and in T-cell activation. Random screening of chemical libraries identified the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor lovastatin as an inhibitor of the LFA-1/intercellular adhesion molecule (ICAM)-1 interaction. The effect of lovastatin on LFA-1 was found to be unrelated to the inhibition of HMG-CoA reductase and to be mediated by lovastatin binding to a novel allosteric site within LFA-1. The biological relevance of LFA-1 inhibition by statins with respect to the overall benefit of this drug class is reviewed. The implications of the statin effect on LFA-1 for future drug design and therapy are discussed.

show abstract

“…The identification of mediators of the IRI cascade (8) has generated new target sites to abrogate its effect using antineutrophil preparations (9), free radical scavengers (10,11), and monoclonal antibodies to block adhesion molecules and the inflammatory cytokine cascade (12)(13)(14)(15). Despite promising results, none have reached widespread clinical use.…”

mentioning

confidence: 99%

Reduction of Ischemia–Reperfusion Injury in the Rat Kidney by FTY720, a Synthetic Derivative of Sphingosine

et al. 2007

View full text Add to dashboard Cite

show abstract

Protective effect of an Anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation

Cited by 17 publications

References 4 publications

Prediction, prevention, and management of delayed graft function: where are we now?

Prediction, prevention, and management of delayed graft function: where are we now?

Lymphocyte Function-Associated Antigen-1 Blockade by Statins: Molecular Basis and Biological Relevance

Reduction of Ischemia–Reperfusion Injury in the Rat Kidney by FTY720, a Synthetic Derivative of Sphingosine

Contact Info

Product

Resources

About